Skip to content

Study · Non-randomized trial · n = 20 · 2007

4 results

Tripartite control of growth hormone secretion in women during controlled estradiol repletion.

Veldhuis JD, Cosma M, Erickson D, Paulo R, Mielke K, Farhy LS, Bowers CY

The Journal of clinical endocrinology and metabolism3 Apr 2007Cited by 5 (Europe PMC)

PMID17405836 (opens in a new tab)DOI10.1210/jc.2007-0043 (opens in a new tab)PepBankPUB-17405836
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In premenopausal women, the order of GH secretagogue potency was GHRP‑2 above GHRH equal to l-arginine, and postmenopausal women lost this order.

    In plain wordsIn women before menopause, GHRP‑2 drove growth hormone release more than GHRH or l-arginine, and women after menopause lost this order.

    Peptide
    GHRP-2
    Outcome
    Not applicableOrder of secretagogue potency in premenopausal women
    Study

    n = 20

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    submaximalAs given in this study (human).

    Source sentences

    Summary
    3) POST women lost the PRE order of secretagogue potency (GHRP-2 > GHRH = l-arginine)
    2 context sentences
    Summary · context
    Subjects included 10 healthy pre- (PRE) and 10 postmenopausal (POST) women.
    Summary · context
    In a defined estradiol (E(2)) milieu, we compared GH secretion after submaximal stimulation with GH-releasing peptide (GHRP)-2 (ghrelin analog), GHRH, and l-arginine (an inhibitor of somatostatin outflow).
  2. 02HumanNon-randomized trialEfficacy outcome

    In the combined cohorts, higher IGF-I concentrations forecast increased GHRP‑2 and GHRH drive of GH secretion.

    In plain wordsIn healthy women, higher IGF-I levels went with a stronger growth hormone response to GHRP‑2 and to GHRH.

    Peptide
    GHRP-2
    Outcome
    IncreaseIGF-I concentration as predictor of GHRP-2-stimulated GH secretion
    Study

    n = 20

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    submaximalAs given in this study (human).

    Source sentences

    Summary
    higher IGF-I concentrations forecast increased GHRP-2 and GHRH drive (R(2) > or = 0.52, P < or = 0.013)
    2 context sentences
    Summary · context
    Subjects included 10 healthy pre- (PRE) and 10 postmenopausal (POST) women.
    Summary · context
    In a defined estradiol (E(2)) milieu, we compared GH secretion after submaximal stimulation with GH-releasing peptide (GHRP)-2 (ghrelin analog), GHRH, and l-arginine (an inhibitor of somatostatin outflow).

Studies that did not test the peptide alone2

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 03HumanNot a test of GHRP-2 aloneNon-randomized trialEfficacy outcome

    In healthy women, age and secretagogue type (GHRP‑2, GHRH, l-arginine) independently determined GH secretion.

    In plain wordsIn healthy women, age and the type of growth hormone stimulus each independently shaped growth hormone release.

    Peptide
    GHRP-2
    Outcome
    Not applicableDeterminants of GH secretion across secretagogues
    Study

    n = 20

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    age (P < 0.001) and secretagogue type (P < 0.001) independently determined GH secretion
    2 context sentences
    Summary · context
    Subjects included 10 healthy pre- (PRE) and 10 postmenopausal (POST) women.
    Summary · context
    In a defined estradiol (E(2)) milieu, we compared GH secretion after submaximal stimulation with GH-releasing peptide (GHRP)-2 (ghrelin analog), GHRH, and l-arginine (an inhibitor of somatostatin outflow).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 04HumanNot a test of GHRP-2 aloneNon-randomized trialEfficacy outcome

    In healthy women, GH responses in postmenopausal subjects were only 26-33% of those in premenopausal subjects across all secretagogues.

    In plain wordsIn healthy women, growth hormone responses after menopause were about a quarter to a third of those before menopause, across all stimuli tested.

    Peptide
    GHRP-2
    Outcome
    DecreaseGH response in postmenopausal versus premenopausal women across all secretagogues
    Study

    n = 20

    Comparator
    Premenopausal women
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH response, postmenopausal relative to premenopausal
    26 to 33%
    all secretagogues

    Source sentences

    Summary
    GH responses in POST subjects were only 26-33% of those in PRE (P < or = 0.002) across all secretagogues
    2 context sentences
    Summary · context
    Subjects included 10 healthy pre- (PRE) and 10 postmenopausal (POST) women.
    Summary · context
    In a defined estradiol (E(2)) milieu, we compared GH secretion after submaximal stimulation with GH-releasing peptide (GHRP)-2 (ghrelin analog), GHRH, and l-arginine (an inhibitor of somatostatin outflow).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.